Fairmont Banff Springs Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

Emerging Technologies in Vaccine Discovery and Development (J5)

joint with the meeting on Progress and Pathways Toward an Effective HIV Vaccine (J6)

Scientific Organizers: David Kaslow, Nicholas Jackson and Ann L. Lee


January 28—February 1, 2018

Fairmont Banff Springs, Banff, Alberta, Canada


Sponsored by Astellas Pharma Inc., Moderna Therapeutics and Pfizer Inc.
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation


Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.
BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.

Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.

Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.

DEADLINES:
*All deadlines end at 11:59 PM US Mountain Standard Time
Global Health Travel Award Deadline: Aug 29, 2017 [details]
Scholarship Deadline: Oct 4, 2017 [details]
Discounted Abstract Deadline: Oct 4, 2017 [details]
Abstract Deadline: Nov 2, 2017 [details]
Discounted Registration Deadline: Dec 6, 2017 [details]

Click here to view Cancellation Policy

Register Yourself Deadlines and Fees

Rates and Deadlines listed below are for the 2018-J5 "Emerging Technologies in Vaccine Discovery and Development" conference only.

*All deadlines end at 11:59 PM US Mountain Standard Time

Deadline Date Cost
Discounted Abstract Deadline
More details
Before and On October 4, 2017 100.00 USD*
- 50.00 USD discount
Abstract Deadline
More details
After October 4, 2017 until December 17, 2017 100.00 USD*
* 50.00 USD of Abstract fee deducted from your registration fee when you register for this meeting
Scholarship
More details
October 4, 2017 n/a
Discounted NON-STUDENT Registration
More details
Before and On December 6, 2017 920.00 USD
(includes 200.00 discount)
Regular NON-STUDENT Registration
More details
After December 6, 2017 1120.00 USD
Discounted STUDENT Registration
More details
Before and On December 6, 2017 695.00 USD
(includes 200.00 discount)
Regular STUDENT Registration
More details
After December 6, 2017 895.00 USD

* Changes in payment type that result in a refund are subject to a processing fee.
* Currency exchange gains/losses are the responsibility of the registrant and the Keystone Symposia will accept no liability for money loss through bank charges, transfers or currency fluctuations.




Discounted Abstract Deadline: October 4, 2017

*All deadlines end at 11:59 PM US Mountain Standard Time

Abstract Submission Fee: 100.00 USD*
Submission by this date receives 50.00 USD discount.
*50.00 USD will be applied to Registration Fee when you register

Abstract Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadlines. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract early allows us to:
  • submit your abstract to organizers to be considered for a short talk
  • accept your abstract online
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
(The Abstract Deadline: is November 2, 2017)

Global Health Travel Award Deadline: August 29, 2017

*All deadlines end at 11:59 PM US Mountain Standard Time


Global Health Travel Award Details: You MUST complete your Global Health Travel Award appplication by the Global Health Travel Award Deadline and complete the other required steps (verify your contact information and submit a recommendation letter) to be considered for a travel award.


Click here to learn more about Global Health Travel Awards.

Scholarship Deadline: October 4, 2017

*All deadlines end at 11:59 PM US Mountain Standard Time


Scholarship Details: You MUST submit your abstract by the Scholarship Deadline and complete the other required steps (submit a scholarship application and submit a mentor letter) to be considered for a scholarship.

Click here to learn more about Scholarships.

Abstract Deadline: November 2, 2017

*All deadlines end at 11:59 PM US Mountain Standard Time


Abstract Submission Fee: 100.00 USD*
*50.00 USD will be applied to Registration Fee when you register

Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadline. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract by the Abstract Deadline allows us to:

  • submit your abstract to organizers to be considered for a short talk
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
Abstracts submitted after the Abstract Deadline will NOT be considered for a short talk.

(Discounted Abstract Deadline: is October 4, 2017)

Discounted Registration Deadline: December 6, 2017

*All deadlines end at 11:59 PM US Mountain Standard Time


Registration Fee: 920.00 USD* (includes 200.00 USD discount)
Student Registration Fee: 695.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

After the Discounted Registration Deadline:


Registration Fee: 1120.00 USD*
Student Registration Fee: 895.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

Registration spaces are limited and may fill prior to discounted registration deadline.

Please be advised that a few meeting participants have received calls and emails from a number of different housing services - "Exhibitors Housing Services", "Global Housing", etc. THESE COMPANIES ARE NOT AFFILIATED WITH KEYSTONE SYMPOSIA and are not authorized by Keystone Symposia to contact you. These companies may tell you that the meeting is filling and seek to take your lodging reservation and obtain your credit card number. We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report to Keystone Symposia any calls or correspondence you might have received and book only through the lodging link on our website, an established travel agency, or directly with the hotel.
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, January 28 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 1 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 2 in order to fully experience the meeting.

SUNDAY, JANUARY 28

16:00—20:00
Arrival and Registration

Van Horne Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Van Horne Foyer

MONDAY, JANUARY 29

07:00—08:00
Breakfast

Mezzanine 2
08:00—09:00
Welcome and Keynote Address
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
* David C. Kaslow, PATH, USA

Penny M. Heaton, Bill & Melinda Gates Medical Research Institute, USA
Introducing the Gates Medical Research Institute: A Vision for Accelerating Translational Development

08:00—09:00
Welcome and Keynote Address
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
* M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA

Michel C. Nussenzweig, HHMI/Rockefeller University, USA
The HIV Vaccine Problem

09:00—11:30
New Tools in Antigen/Vaccine Discovery
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
* Pamela J. Bjorkman, California Institute of Technology, USA

Tobias Kollmann, University of British Columbia, Canada
Decoding the Human Immune System to Accelerate Vaccine Development

Coffee Break

Simon Delagrave, Sanofi Pasteur, USA
Novel Antigen Design and Functional Immune Assessments

Rafick-Pierre Sekaly, Case Western Reserve University, USA
Systems Biology and Vaccine Discovery

Sarah F. Andrews, National Institutes of Health, USA
Short Talk: Single-Cell Characterization of the Recall and de novo Responses in Humans to Influenza Hemagglutinin

Hana Golding, US Food and Drug Administration, USA
Short Talk: Impact of AS03 Adjuvant on Antibody Repertoires and Affinity Maturation Against H5N1 Pandemic Influenza Vaccines and Heterologous Neutralization

09:00—11:30
Laying the Foundation for an HIV Vaccine
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
Dennis R. Burton, The Scripps Research Institute, USA
Neutralizing HIV Antibodies and Protection

Coffee Break

Barton F. Haynes, Duke University Medical Center, USA
Host Controls of Broadly Neutralizing Antibodies

* M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
Early Clinical Concepts to Advanced Stage HIV Vaccine Studies

Daniel Stieh, Johnson & Johnson, Netherlands
Short Talk: Interim Immunogenicity Analysis of TRAVERSE: A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind phase 1/2a Study in HIV Uninfected Adults to Assess Safety/Tolerability and Immunogenicity of Two Different Prime/Boost Regimens

Tomas Hanke, University of Oxford, UK
Short Talk: Clinical Development of the First -Generation Conserved Region T Cell Vaccines

11:30—17:00
On Own for Lunch

11:30—13:00
Poster Setup

Mezzanine 2
13:00—22:00
Poster Viewing

Mezzanine 2
14:30—16:30
Workshop 1: Assessing Immunogenicity in Animals to Predict Outcomes in Humans

Van Horne C
* Richard Malley, Boston Children's Hospital, USA

Lenny Moise, EpiVax, USA
Immune Engineered H7N9 Influenza Hemagglutinin Overcomes Poor Vaccine Immunogenicity

Clare N. Burn, Albert Einstein College of Medicine, USA
An HSV Vaccine Candidate Deleted in Glycoprotein D Elicits High Titer FcγRIV-Activating Antibodies that Protect against HSV Challenge: A Role for HVEM in Functional Immune Responses

Ian Francis, Boston University, USA
Neisseria Gonorrhoeae Outer Membrane Vesicles Lacking RMP Show Promise as a Vaccine Antigen

Raphael Simon, University of Maryland School of Medicine, USA
Preclinical Development of a Glycoconjugate Vaccine for Sub-Saharan Africa to Prevent Typhoid and Invasive Nontyphoidal Salmonella Disease

Emmanuel Amlabu, University of Ghana, Ghana
Functional Characterization of Plasmodium Falciparum Surface Related Protein (PfSRP) as a Potential Blood-Stage Vaccine Target

Mariette Barbier, West Virginia University, USA
Development of Vaccines against P. Aeruginosa based on Iron Acquisition

Jian-Dong Huang, University of Hong Kong, China
Combination of Multiple Antigens are Essential for the Development of a Novel Vaccine Against Staphylococcus aureus Infection

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Structural Immunology Guiding Vaccine Development (Joint)
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
* Pamela J. Bjorkman, California Institute of Technology, USA
Structural Studies of Antibody and Receptor Binding to HIV-1 Env

Jason S. McLellan, University of Texas at Austin, USA
Structure-Based Vaccine Design for Class I Viral Fusion Glycoproteins

Andrew B. Ward, The Scripps Research Institute, USA
Using Structures to Guide Env Immunogen Design and Redesign

Walther Mothes, Yale University School of Medicine, USA
Short Talk: Associating HIV-1 Env Trimer Structures with Functional Env Conformational States by smFRET Analysis

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
19:30—22:00
Poster Session 1

Mezzanine 2

TUESDAY, JANUARY 30

07:00—08:00
Breakfast

Mezzanine 2
08:00—11:30
New Platforms for Active Immunization
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
* Louis J. Picker, Oregon Health & Science University, USA

Klaus Früh, Oregon Health & Science University, USA
CMV-Vectored Vaccines for Eliciting Cellular Immunity

Justin Moran, Pfizer Inc., USA
Multi-Component Vaccines Are the Future but Pose Development Challenges

Coffee Break

Richard Malley, Boston Children's Hospital, USA
Generating Broad B- and T-Cell Immunity via the Multiple Antigen-Presenting System (MAPS)

Christine Shaw, Moderna Therapeutics, USA
Targeting Viral Pathogens with mRNA-Based Vaccines

Tong-Ming Fu, Merck Research Laboratories, USA
Short Talk: A Replication-Defective Human Cytomegalovirus Vaccine for Prevention of Congenital Infection

Nadia Oreshkova, Leiden University Medical Center, Netherlands
Short Talk: Engineering Yellow Fever Virus 17D-based RNA Replicons into an Innovative DNA-Launched Vaccine Vector Platform

Jean-Philippe Julien, Hospital for Sick Children Research Institute, Canada
Short Talk: Structural Studies of Human Antibody Responses to Malaria Vaccine Antigen PfCSP

08:00—11:15
Germinal Centers, B/T Cell Interactions
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
* Shane Crotty, La Jolla Institute for Allergy and Immunology, USA
Assessing the Engines of Affinity Maturation: Germinal Centers and Tfh Cells

Gabriel D. Victora, Rockefeller University, USA
Antibody Affinity Maturation in Germinal Centers

Coffee Break

Facundo D. Batista, Ragon Institute of MGH, MIT and Harvard, USA
B Cell Activation Induces a Switch from Canonical to Non-Canonical Autophagy that Shapes B Cell Fate

Garnett H. Kelsoe, Duke University and Medical Center, USA
Mechanisms of Selection in Germinal Centers

Omolara Olujimi Baiyegunhi, University of KwaZulu-Natal, South Africa
Short Talk: Early Initiation of Antiretroviral Therapy during Hyperacute HIV-1 Infection Preserves T Follicular Helper Cell Function

Ben Read, Massachusetts Institute of Technology, USA
Short Talk: Nanoparticle Delivery, Glycosylation and Host Complement Target Env Immunogens to the Germinal Center

11:30—17:00
On Own for Lunch

11:30—13:00
Poster Setup

Mezzanine 2
11:30—13:00
Hands-On Computer Session on Los Alamos Sequence Database
HIV Database Workshop presented by Los Alamos National Laboratory staff Topics include: • HIV Sequence Database • Bioinformatics tools that have general application Users can register for either or both workshops. Bring your own laptop.

Baron Shaughnessy
13:00—22:00
Poster Viewing

Mezzanine 2
14:30—16:30
Workshop 2: Epidemic Preparedness Innovation

Van Horne C
* David C. Kaslow, PATH, USA
Just-in-Time and Just-in-Case Vaccines Approaches to Epidemic Preparedness

Christine Dahlke, University Medical Center Hamburg-Eppendorf, Germany
Human miRNome Profiling Identifies a MicroRNA Signature Induced by the Ebola Vaccine rVSV-EBOV

Tulika Singh, Duke University, USA
Transplacental Transfer of IgG in the Setting of Zika Virus Infection during Pregnancy

Neal Scott Van Hoeven, Infectious Disease Research Institute, USA
Development of a Flexible Replicating Viral RNA Vaccine Platform and Generation of a Candidate Vaccine for Zika Virus

Emma M. Kennedy, Public Health England, UK
Development of a Vaccine for Lassa Fever using Modified Vaccinia Ankara Virus as a Vector

Nianshuang Wang, University of Texas at Austin, USA
Structure-Based Design of Prefusion Coronavirus Spikes with Enhanced Expression, Stability and Immunogenicity

Jingjing Jiang, Inovio Pharmaceuticals, USA
Immunogenicity of a Multivalent Mosquito-Borne Virus DNA Vaccine in Non-Human Primates

14:30—16:30
Workshop 1: Laying the Groundwork for Vaccine Design

Van Horne A/B
* Marie Pancera, Fred Hutchinson Cancer Research Center, USA

* Michael Farzan, The Scripps Research Institute, USA

Christopher Andrew Cottrell, The Scripps Research Institute, USA
Using High-Resolution Cryo-Electron Microscopy to Guide Iterative Structure-Based HIV Vaccine Design

Christopher O. Barnes, California Institute of Technology, USA
Structural Characterization of a Highly Potent V3-Targeting Broadly Neutralizing Antibody Bound to Natively-Glycosylated HIV-1 Envelope

Jose Maximiliano Medina-Ramírez, University of Amsterdam, Netherlands
Sequential Vaccination Regimens Based on Multiclade Germline-Targeting Trimers and Affinity Intermediates to Guide bNAb Development

Jason J. Gorman, NIAID, National Institutes of Health, USA
Stabilization of Soluble SIV Envelope Trimers

Wilton Bryan Williams, Duke University, USA
SHIV-CH848 Infection of Rhesus Macaques Recapitulates HIV-1 Env-Antibody Co-Evolution of Humans

Tara A. Bancroft, Fred Hutchinson Cancer Research Center, USA
Detection and in vivo Activation of Naive B Cells Expressing Putative Germline Precursors of a Neutralizing Antibody using Anti-Idiotypes

Devin Sok, International AIDS Vaccine Initiative, USA
Non-human Primate Pharmacokinetics Evaluation of Broadly Neutralizing Antibodies Isolated from Cow Immunizations

Claudia Cicala, NIAID, National Institutes of Health, USA
Non-Neutralizing HIV gp120 V2 Domain Specific Antibodies Derived from HIV and SIV Infection and Vaccination Inhibit gp120 Binding to Integrin α4β7

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
New Platforms for Passive Immunization
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
* Charles Richter King, PATH, Malaria Vaccine Initiative, USA

JoAnn A. Suzich, MedImmune, USA
Multi-Mechanistic Monoclonal Antibody-Based Approaches for Passive Immunoprophylaxis

Alejandro Balazs, Massachusetts General Hospital, USA
Development of Vectored Immunotherapy Reveals Escapability as a Key Feature of Broadly Neutralizing Antibodies

Amar Kumar Garg, Indian Institute of Science, India
Short Talk: Stochastic Simulation of Affinity Maturation in Germinal Centers Suggest Optimal Passive Immunization Protocols

Steven E. Bosinger, Emory University, USA
Short Talk: BALDR - A Computational Pipeline for Linking Paired Immunoglobulin Heavy and Light Chain to Gene Expression for Single-Cells in Vaccine Studies

Cody S. Nelson, Duke University, USA
Short Talk: HCMV Glycoprotein B Vaccine Efficacy Likely Mediated by Non-Neutralizing Antibody Effector Functions

17:00—19:00
Model Systems for HIV Vaccine Development
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
* George M. Shaw, University of Pennsylvania, USA
Recapitulation of HIV-1 Envelope-Antibody Coevolution in Rhesus Macaques Leading to Strain-Specific and Broadly Neutralizing Antibodies

Pia Dosenovic, Rockefeller University, USA
Activation of HIV-1-Specific B Cell Precursors in the Presence of a Polyclonal Immune System

Andres Finzi, CRCHUM, Université de Montréal, Canada
Impact of Env Conformation on ADCC Responses

Ann J. Hessell, Oregon Health & Science University, USA
Short Talk: Targeting V1V2 Epitopes for the Development of an Effective HIV Vaccine

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
19:30—22:00
Poster Session 2

Mezzanine 2

WEDNESDAY, JANUARY 31

07:00—08:00
Breakfast

Mezzanine 2
08:00—11:00
New Tools in Interrogating Human Immune Responses (Joint)
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
* Bette Tina Marie Korber, Los Alamos National Laboratory, USA
Computational Tools for Antigen Design

William H. Robinson, Stanford University School of Medicine, USA
Sequencing the Functional Antibody Repertoire

Coffee Break

Louis J. Picker, Oregon Health & Science University, USA
Immune Programming with CMV Vectors

Anna P. Durbin, Johns Hopkins Bloomberg School of Public Health, USA
Characterizing the Cellular and Humoral Response of Human Volunteers following Dengue Vaccination and Challenge in a Dengue Controlled Human Infection Model

Ian Setliff, Vanderbilt Vaccine Center, USA
Short Talk: Identification of Public Antibody Clonotypes in HIV-1 Infection

11:00—17:00
On Own for Lunch

11:00—13:00
Poster Setup

Mezzanine 2
11:30—13:00
Hands-On Computer Session on Los Alamos Immunology Database
HIV Database Workshop presented by Los Alamos National Laboratory staff Topics include: • HIV Immunology Database • Immunology and vaccine design tools that have general application Users can register for either or both workshops. Bring your own laptop.

Baron Shaughnessy
13:00—22:00
Poster Viewing

Mezzanine 2
14:30—16:30
Workshop 2: Clinical and Preclinical Vaccine Studies

Van Horne A/B
* Nancy L. Haigwood, Oregon Health & Science University, USA

* Alejandro Balazs, Massachusetts General Hospital, USA

Andrew Jones, Emory University, USA
Sublingual and Buccal Delivery of MVA/Protein HIV Vaccination with a Needle-Free Injector Induces Robust Systemic and Mucosal Antibody Responses in Rhesus Macaques

Barbara K. Felber, NCI, National Institutes of Health, USA
DNA+Protein HIV Vaccine Protection against SHIV Challenge upon Same-Site Administration in Macaques

Matthias Pauthner, The Scripps Research Institute, USA
Vaccine-Induced Protection from Autologous Tier 2 SHIV-BG505 Challenge

Keyun Wang, NIAID, National Institutes of Health, USA
Trispecific Broadly Neutralizing HIV Antibodies Mediate Potent SHIV Protection in Macaques

Kristen W. Cohen, Fred Hutchinson Cancer Research Center, USA
Expansion of VH1-2*02 Env-Specific B Cells by Vaccination

Tongqing Zhou, NIAID, National Institutes of Health, USA
Priming with Glycan-deleted HIV-1 Env Trimers and Sequential Boosting with Glycan-Restored Immunogens Induces Immune Responses that Neutralize Diverse Tier-2 Viruses

Daniel P. Leaman, The Scripps Research Institute, USA
Membrane Env Liposomes as a Platform for Immunization with Membrane-Incorporated HIV Env Spikes

Jon Steichen, The Scripps Research Institute, USA
Germline-Targeting for HCDR3-Dependent Broadly Neutralizing Antibodies

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
New Approaches in Vaccine Clinical Trial Design
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
* Anna P. Durbin, Johns Hopkins Bloomberg School of Public Health, USA

Thomas Evans, TomegaVax, USA
Mathematical Modeling of Human Immune Responses to Design more Efficient Vaccine Clinical Development

Ashley J. Birkett, PATH Malaria Vaccine Initiative, USA
New Approaches in Vaccine Clinical Trial Design: Maximizing Malaria Vaccine Efficacy and Informing Next-Generation Efforts

Chris Gast, PATH, USA
Novel and More Efficient Vaccine Clinical Trials using Adaptive Designs

Maryam Mukhamedova, NIAID, National Institutes of Health, USA
Short Talk: RSV Antibody Repertoire Analysis from Memory B Cells from RSV DS-Cav1-Vaccinated Adult Volunteers

17:00—19:15
New Insights into HIV/SIV Env Biology and the Function of Non-neutralizing Antibodies
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
Stuart J. Neil, King's College London, UK
Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction

* Beatrice H. Hahn, University of Pennsylvania, USA
Determinants of HIV-1 Transmission Fitness

Michael Farzan, The Scripps Research Institute, USA
AAV-eCD4-Ig Affords Robust Protection from both SHIV-AD8 and SIVmac239

Lars Hangartner, The Scripps Research Institute, USA
Short Talk: Low-Dose PGT121 Sterilely Protects Macaques in an FcγR-independent Manner from Vaginal Challenge with SHIVSF163P3

Susan Zolla-Pazner, Icahn School of Medicine at Mount Sinai, USA
Short Talk: Induction with V1V2-scaffold Protein Immunogens of Cross-Clade Reactive V2-specific Effector Antibodies with Fc-Mediated Antiviral Functions

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
19:30—22:00
Poster Session 3

Mezzanine 2

THURSDAY, FEBRUARY 1

07:00—08:00
Breakfast

Mezzanine 2
08:00—11:30
New Tools in Vaccine Manufacturing and Product Analytics
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
* Andrew Lees, Fina BioSolutions, USA

Sangeetha L. Sagar, Sanofi Pasteur, USA
Advances and Challenges in Vaccine Development and Manufacture

James N. Thomas, Just Biotherapeutics, USA
Low-Cost Manufacturing and more Stable Immunobiologics for Use in Low and Middle Income Countries

Coffee Break

Ann L. Lee, Juno Therapeutics, USA
Smart Bioprocessing Strategies for Immunobiologics

Phillip W. Berman, University of California, Santa Cruz, USA
Breaking the Logjam in HIV Envelope Vaccine Production: Robotics and Gene Editing to Improve Upstream and Downstream Manufacturing Processes

Mark S. Fife, Pirbright Institute, UK
Short Talk: Gene Knockout Technology of Chicken Interferon Inducible Transmembrane Proteins (chIFITMs) for Increased Vaccine Production

Gabriel Byrne, University of California, Santa Cruz, USA
Short Talk: Use of Gene Editing for the Development of an Mgat1 Deficient CHO Cell Line Suitable for GMP Manufacturing of HIV Vaccines

Caroline B. Kjaerulff Mathiesen, Metropolitan University College, University of Copenhagen, Denmark
Short Talk: Genetically Engineered Cell Factories Produce Glycoengineered Vaccines that Target Antigen Presenting Cells and Alter Immunity

08:00—11:15
Induction of Broad Neutralizing Antibodies by Vaccination
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
Leonidas Stamatatos, Fred Hutchinson Cancer Research Center, USA
Targeted Expansion and Maturation of bNAb B Cell Precursors

* John R. Mascola, NIAID, National Institutes of Health, USA
Strategies to Elicit HIV-1 Fusion Peptide Directed Neutralizing Antibodies

Coffee Break

William Schief, IAVI and The Scripps Research Institute, USA
Toward Elicitation of Broadly Neutralizing Antibodies by Germline-Targeted Priming and Structure-Guided Boosting

Rogier W. Sanders, Weill Medical College of Cornell University, USA
Native-Like HIV-1 Envelope Trimers as a Platform to Activate Germline Precursors of Broadly Neutralizing Antibodies

Nicole A. Doria-Rose, NIAID, National Institutes of Health, USA
Short Talk: Development of Three MPER-directed Neutralizing Antibody Lineages in an HIV Infected Individual

Kevin O. Saunders, Duke University, USA
Short Talk: Modification of HIV Env Glycosylation Augments Binding to Unmutated Common Ancestor and Intermediate Antibodies of V3-Glycan Broadly Neutralizing Antibody Lineages

11:30—17:00
On Own for Lunch

14:30—16:30
Workshop 3: How Best to Meet the Increasing Challenges Faced in Vaccine Development

Van Horne C
* Tong-Ming Fu, Merck Research Laboratories, USA

Bruno Emanuel Correia, École Polytechnique Fédérale de Lausanne, Switzerland
On the Development of Precision Vaccines through Epitope-Focused Immunogens: A Case Study on RSV

Lan Zhang, Merck, USA
Design and Characterization of an Improved Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

Michael J. Moser, FluGen, Inc., USA
Single-Replication Influenza B Virus Vaccine BM2SR Provides Sterilizing Immunity and Cross-Lineage Protection by Inducing both Cellular and Cytokine Responses in Mice

Masaru Kanekiyo, NIAID, National Institutes of Health, USA
Targeting the Conserved Stem Supersite on Influenza Virus Hemagglutinin by Human Ighd-Encoded Innate-Like Element

Rahul Shukla, International Centre for Genetic Engineering and Biotechnology, India
“Four-in-One” Envelope-based mosaic VLPs Elicit Tetravalent Neutralizing Antibody Response Devoid of Enhancement Potential in Mice

Guangzu Zhao, University of Queensland, Australia
Self-Adjuvanting and Self-Assembling Lipid Core Peptide Vaccines against Human Hookworm Parasite

Wessam Melik, Orebro University, Sweden
Development of an Edible TBEV Vaccine

Rocio Jimenez-Martinez, Griffith University-QIMRB, Australia
Investigating Venom Derived Molecules that Augment Human Immune Function

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—18:45
New Tools in Vaccine Formulation and Delivery
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
* David C. Kaslow, PATH, USA

Nathalie Garçon, Bioaster, France
Adjuvants in Vaccines: From Aluminium to AS01: What Path for their Development and Licensure?

Rhea N. Coler, Infectious Disease Research Institute, USA
Enhancing Immunogenicity and Protective Efficacy through Novel Adjuvants and Formulations

Mark C. Poznansky, Massachusetts General Hospital, USA
Accelerated Development of a T Cell-Based Vaccine for Q Fever

17:00—19:00
Antibodies as Immunoprophylaxis and Treatment
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
Marina F. Caskey, Rockefeller University, USA
Effects of Potent Broad Neutralizing Antibody Combinations in Humans

Julie Ledgerwood, NIAID, National Institutes of Health, USA
Passive Immunization of HIV-1 Neutralizing Monoclonal Antibodies in Clinical Trials

* David D. Ho, Aaron Diamond AIDS Research Center, USA
Engineering HIV-Neutralizing Bispecific Antibodies

Peter D. Kwong, NIAID, National Institutes of Health, USA
Short Talk: Recognition by Antibody of All Major Exposed Regions of the Prefusion Closed HIV-1 Env Trimer

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
19:00—19:15
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Alberta/New Brunswick
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Alberta/New Brunswick

FRIDAY, FEBRUARY 2

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Astellas Pharma Inc. Bill & Melinda Gates Foundation
Moderna Therapeutics Pfizer Inc.

We gratefully acknowledge additional support for this conference from:

Avanti Polar Lipids, Inc.

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Sanofi US


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676